Breast Cancer Index® Included in Guidelines
Cancer
Index
Breast Cancer Index (BCI) is the only genomic test recognized by the NCCN and the ASCO® Clinical Practice Guideline to predict which patients are likely to benefit from extension of adjuvant anti-estrogen therapy beyond 5 years.1,2
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the ASCO® Clinical Practice Guideline identify BCI as the only genomic test to predict which patients are likely to benefit from extension of adjuvant anti-estrogen therapy beyond 5 years.The inclusion of BCI in both guidelines supports its routine clinical use in node-negative and node-positive (1-3 nodes) patients across anti-estrogen therapies, including tamoxifen and aromatase inhibitors, based on the test’s comprehensive predictive evidence.
Guideline Inclusion
- In secondary analyses of the MA.17, Trans-aTTom and IDEAL trials, patients with HR-positive, T1-T3, pN0 or pN+ who had a BCI (H/I) high-demonstrated significant improvements in DFS when adjuvant endocrine therapy was extended, compared to the control arm
- In contrast, BCI (H/I) low patients derived no benefit from extended adjuvant therapy
- The ASCO® Clinical Practice Guideline (Guideline Update 1.24): If a patient has node-negative or node-positive breast cancer with 1-3 positive nodes and has been treated with 5 years of primary endocrine therapy without evidence of recurrence, the clinician may offer the BCI test to help guide decisions about extended endocrine therapy with either tamoxifen, an AI, or a sequence of tamoxifen followed by AI
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed February 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Andre F et al. J Clin Oncol. Published online April 19, 2022. DOI: 10.1200/JCO.22.00069. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to https://ascopubs.org/jco/special/guidelines [ascopubs.org]. ASCO® Clinical Practice Guideline makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way.
Back To All
